EP3294283

NOVARTIS AG
Application Number
EP16722388A
Filing Date
May 9, 2016
Status
Granted And Under Opposition
Feb 3, 2023
Grant Date
Mar 8, 2023
External Links
Slate, Register

Biblio Summary

The patent EP3294283B1 was granted on Mar 8, 2023 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 15 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BULLE DR., JANDec 8, 2023ADMISSIBLE
KRKA, D.D., NOVO MESTODec 8, 2023ADMISSIBLE
ZENTIVA, K.S.Dec 8, 2023ADMISSIBLE
ALFRED E. TIEFENBACHER (GMBH & CO. KG)Dec 7, 2023ADMISSIBLE
BETAPHARM ARZNEIMITTEL GMBHDec 7, 2023ADMISSIBLE
GENERICS UKDec 7, 2023ADMISSIBLE
SANOVEL IIAC SAN. VE TIC. A.SDec 7, 2023ADMISSIBLE
STRAWMAN LIMITEDDec 7, 2023ADMISSIBLE
SYNTHON BVDec 7, 2023ADMISSIBLE
TEVADec 7, 2023ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Dec 7, 2023ADMISSIBLE
HOFFMANN EITLEDec 4, 2023ADMISSIBLE
DR. SCHON, NEYMEYR & PARTNER PATENTANWALTE MBBNov 30, 2023ADMISSIBLE
CAMULON LIMITEDNov 23, 2023ADMISSIBLE
EGIS GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAGOct 9, 2023ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245